药物的新奇特征与更大的健康益处有关吗?
A Alex Levine1, Daniel E Enright2, Katherine A Clifford2
1Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA. aalevine@bu.edu.
Applied health economics and health policy
|September 3, 2024
概括
与标准治疗相比,新药提供了更大的健康益处,以质量调整的寿命年 (QALYs) 衡量. 这些发现强调了新药在改善患者治疗结果方面的价值.
科学领域:
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
- 药物开发 药物开发
背景情况:
- 评估新疗法的价值对于医疗保健决策至关重要.
- 经质量调整的寿命年 (QALYs) 是量化健康收益的标准指标.
- 了解药物新性与健康结果之间的联系,有助于药物开发和药品退款.
研究的目的:
- 研究新药特征与增量健康益处之间的关联.
- 以QALYs相对于护理标准来量化健康收益.
- 确定与更大的健康益处相关的特定新奇特征.
主要方法:
- 分析了美国FDA (1999-2018) 批准的药物指示对.
- 从已发表的文献中提取了增量QALY收益.
- 药物新性是由六个二元特征定义的,包括作用机制和指示类型.
- 进行了双变量和多变量回归分析.
主要成果:
- 新药指示对比非新药对的中位数和平均QALY收益更高.
- 大多数新奇特征都显示出与QALY收益的显著双变异关联.
- 多变量模型证实了新奇特征和QALY增长之间的独立关联,不包括未满足的需求和罕见疾病的指示.
结论:
- 具有新奇特征的药物与优越的健康益处有关.
- 这些发现支持了药物开发创新的价值.
- 未来的研究应该探索与新药相关的成本效益和获取.
相关概念视频
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Drug Discovery: Overview
7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K
Structure-Activity Relationships and Drug Design
679
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
679
Effects of Chemicals: Overview
1.2K
Drugs, encompassing various chemical compounds from natural sources, lab synthesis, or genetic engineering, elicit different biological responses in living organisms. Some of these responses are desirable or therapeutic, while others are undesirable. The primary goal of administering a drug is to achieve a therapeutic effect, that is, to address a specific disease or health condition. Any concurrent effects outside of this therapeutic outcome are considered undesirable. These undesirable...
1.2K
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789


